Neoadjuvant PRRT with 90Y-DOTATOC: Preliminary results from a monocentric perspective study

#4115

Introduction: Surgery is considered the only curative treatment for pancreatic neuroendocrine tumors (pNETs), but it is feasible only in a few patients. A new possible strategy in pNETs is preoperative PRRT, as its cytoreductive effect could increase the efficacy of surgery.

Aim(s): The aim of this perspective study is to evaluate the response and rate of R0 surgery in patients with unresectable/borderline resectable G1/G2 pNET eligible to PRRT with 90Y-DOTATOC and associate the response to circulating NET transcripts measured before and after PRRT.

Materials and methods: This study includes patients with histopathologic diagnosis of unresectable/borderline resectable G1/G2 pNET, with limited liver disease based on pre-treatment 68Ga-DOTATOC PET/CT. To date, 11 out 30 patients (6 males and 5 females) were enrolled. All patients received at least one cycle of 1.85 GBq of 90Y-DOTATOC; the protocol foresaw a cumulative activity of 9.25-11.1 GBq in 5-6 cycles. Moreover, a dosimetric study on kidneys is performed.

Conference:

Presenting Author:

Authors: Barone A, Grana C, Papi S, Bertani E, Rocca P,

Keywords: PRRT, 90Y-DOTATOC, Neoadjuvant PRRT, pancreatic NET,